Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Looks To Buy Icagen To Fold Into Neusentis Pain Research Unit

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer plans to buy its pain partner in a deal valued at $56 million, including the 11% of shares the big pharma already owns in Icagen.

You may also be interested in...



Teva/Xenon’s Pain Ointment Failure Leaves Sparser Nav1.7 Pipeline

Once highly anticipated as an alternative mechanism for pain, the Nav1.7 target suffered another blow with Teva/Xenon’s failure of TV-45070 in osteoarthritis, though the class may still work in neuropathic pain.

Xenon Feels No Pain After $41M Upfront From Teva

Teva and Xenon collaborate to develop the Canadian company’s lead pain product; the deal could net Xenon as much as $376 million and will fit snugly into the Israeli company’s new focus.

Genentech Partners In Pain With Xenon

As part of its burgeoning efforts in neuroscience, Genentech will discover and develop compounds and companion diagnostics for the treatment of pain, not an area the company historically has played in.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel